Arnold Lippa - Net Worth and Insider Trading

Arnold Lippa Net Worth

The estimated net worth of Arnold Lippa is at least $3 Million dollars as of 2024-05-25. Arnold Lippa is the Member of 10% owner group of Core Lithium Corp and owns about 2,971,792 shares of Core Lithium Corp (CORX) stock worth over $3 Million. Details can be seen in Arnold Lippa's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Arnold Lippa has not made any transactions after 2013-03-22 and currently still holds the listed stock(s).

Transaction Summary of Arnold Lippa

To

Arnold Lippa Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Arnold Lippa owns 2 companies in total, including RespireRx Pharmaceuticals Inc (RSPI) , and Hepion Pharmaceuticals Inc (HEPA) .

Click here to see the complete history of Arnold Lippa’s form 4 insider trades.

Insider Ownership Summary of Arnold Lippa

Ticker Comapny Transaction Date Type of Owner
RSPI RespireRx Pharmaceuticals Inc 2013-03-22 director & Chairman & CEO and President & other: Member of 10% owner group
HEPA Hepion Pharmaceuticals Inc 2015-11-30 director

Arnold Lippa Latest Holdings Summary

Arnold Lippa currently owns a total of 1 stock. Arnold Lippa owns 2,971,792 shares of Core Lithium Corp (CORX) as of March 22, 2013, with a value of $3 Million.

Latest Holdings of Arnold Lippa

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
CORX Core Lithium Corp 2013-03-22 2,971,792 1.00 2,971,792

Holding Weightings of Arnold Lippa


Arnold Lippa Form 4 Trading Tracker

According to the SEC Form 4 filings, Arnold Lippa has made a total of 0 transactions in Core Lithium Corp (CORX) over the past 5 years. The most-recent trade in Core Lithium Corp is the sale of 0 shares on March 22, 2013, which brought Arnold Lippa around $0.

Insider Trading History of Arnold Lippa

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Arnold Lippa Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Arnold Lippa Ownership Network

Ownership Network List of Arnold Lippa

No Data

Ownership Network Relation of Arnold Lippa


Arnold Lippa Owned Company Details

What does RespireRx Pharmaceuticals Inc do?

Who are the key executives at RespireRx Pharmaceuticals Inc?

Arnold Lippa is the director & Chairman & CEO and President & other: Member of 10% owner group of RespireRx Pharmaceuticals Inc. Other key executives at RespireRx Pharmaceuticals Inc include SVP of Pre-Clinical Prod. Dev. David Dickason , director & CEO and President Timothy L. Jones , and director & President & CEO Manuso James S J .

RespireRx Pharmaceuticals Inc (RSPI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of RespireRx Pharmaceuticals Inc (RSPI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of RespireRx Pharmaceuticals Inc (RSPI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

RespireRx Pharmaceuticals Inc (RSPI)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

RespireRx Pharmaceuticals Inc Insider Transactions

No Available Data

Arnold Lippa Mailing Address

Above is the net worth, insider trading, and ownership report for Arnold Lippa. You might contact Arnold Lippa via mailing address: C/o Aurora Capital, Llc, 17 Park Avenue, #201, New York Ny 10016.

Discussions on Arnold Lippa

No discussions yet.